Literature DB >> 28123733

Increased serum leptin level in overweight patients with colon carcinoma: A cross-sectional and prospective study.

Di Wang1, Lichen Gao2, Kuiyu Gong1, Qin Chai1, Guihua Wang1.   

Abstract

Leptin is associated with carcinogenesis and progression of various cancers. However, the changes of the serum leptin level in Chinese overweight patients with colon carcinoma and its association with response to treatment in these patients have rarely been investigated. A total of 63 Chinese overweight patients with colon cancer and 40 body mass index-matched control subjects were recruited in the present study. The serum leptin levels of colon cancer patients prior to and 21 days after colectomy, as well as those of healthy controls, were measured and compared. In addition, the focal expression of phosphorylated Akt, mammalian target of rapamycin and 70S6 Kinase (p-Akt, p-mTOR and P-70S6 Kinase) and leptin were determined in the resected specimens and the correlation between serum leptin levels and the focally expressed markers were investigated. The serum leptin levels of colon cancer patients were significantly higher compared with those of the controls (22.67±12.56 vs. 12.68±7.8 ng/ml, respectively; P<0.05). Moreover, the leptin levels decreased after the operation when compared to the preoperative levels (18.67±8.54 vs. 22.67±12.56 ng/ml, respectively; P<0.05). In addition, there was a significant correlation between the serum leptin levels and the focal expression of p-Akt, p-mTOR, P-70S6 Kinase and leptin (P<0.05). In conclusion, the leptin levels were elevated in Chinese overweight patients with colon cance these levels decreased following colectomy, indicating that leptin may be associated with colon carcinogenesis. Thus, serum leptin level may be used for early diagnosis and for monitoring the response to treatment of colon carcinoma in overweight Chinese patients.

Entities:  

Keywords:  Chinese; body mass index; colon carcinoma; overweight; serum leptin

Year:  2016        PMID: 28123733      PMCID: PMC5244862          DOI: 10.3892/mco.2016.1087

Source DB:  PubMed          Journal:  Mol Clin Oncol        ISSN: 2049-9450


  12 in total

Review 1.  Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms.

Authors:  Eugenia E Calle; Rudolf Kaaks
Journal:  Nat Rev Cancer       Date:  2004-08       Impact factor: 60.716

Review 2.  Leptin and cancer.

Authors:  Cecilia Garofalo; Eva Surmacz
Journal:  J Cell Physiol       Date:  2006-04       Impact factor: 6.384

3.  Adipocytokines as new promising markers of colorectal tumors: adiponectin for colorectal adenoma, and resistin and visfatin for colorectal cancer.

Authors:  Takako Eguchi Nakajima; Yasuhide Yamada; Tetsutaro Hamano; Koh Furuta; Takahisa Matsuda; Shin Fujita; Ken Kato; Tetsuya Hamaguchi; Yasuhiro Shimada
Journal:  Cancer Sci       Date:  2010-01-31       Impact factor: 6.716

Review 4.  Increasing incidence of colorectal cancer in Asia: implications for screening.

Authors:  Joseph J Y Sung; James Y W Lau; K L Goh; W K Leung
Journal:  Lancet Oncol       Date:  2005-11       Impact factor: 41.316

5.  Leptin regulates proliferation and apoptosis of colorectal carcinoma through PI3K/Akt/mTOR signalling pathway.

Authors:  Di Wang; Jian Chen; Hui Chen; Zhi Duan; Qimei Xu; Meiyan Wei; Lianghua Wang; Meizuo Zhong
Journal:  J Biosci       Date:  2012-03       Impact factor: 1.826

6.  Leptin levels in human and rodent: measurement of plasma leptin and ob RNA in obese and weight-reduced subjects.

Authors:  M Maffei; J Halaas; E Ravussin; R E Pratley; G H Lee; Y Zhang; H Fei; S Kim; R Lallone; S Ranganathan
Journal:  Nat Med       Date:  1995-11       Impact factor: 53.440

7.  Serum immunoreactive-leptin concentrations in normal-weight and obese humans.

Authors:  R V Considine; M K Sinha; M L Heiman; A Kriauciunas; T W Stephens; M R Nyce; J P Ohannesian; C C Marco; L J McKee; T L Bauer
Journal:  N Engl J Med       Date:  1996-02-01       Impact factor: 91.245

8.  Serum leptin, adiponectin, and resistin concentration in colorectal adenoma and carcinoma (CC) patients.

Authors:  Anna Kumor; Piotr Daniel; Mirosława Pietruczuk; Ewa Małecka-Panas
Journal:  Int J Colorectal Dis       Date:  2008-11-01       Impact factor: 2.571

9.  Leptin concentrations, leptin receptor polymorphisms, and colorectal adenoma risk.

Authors:  Victoria M Chia; Polly A Newcomb; Johanna W Lampe; Emily White; Margaret T Mandelson; Anne McTiernan; John D Potter
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2007-12       Impact factor: 4.254

Review 10.  Leptin--from a signal of adiposity to a hormonal mediator in peripheral tissues.

Authors:  Mario Baratta
Journal:  Med Sci Monit       Date:  2002-12
View more
  3 in total

1.  Relationship between Barrett's esophagus and colonic diseases: a role for colonoscopy in Barrett's surveillance.

Authors:  Yuji Amano; Ryotaro Nakahara; Takafumi Yuki; Daisuke Murakami; Tetsuro Ujihara; Iwaki Tomoyuki; Ryota Sagami; Satoshi Suehiro; Yasushi Katsuyama; Kenji Hayasaka; Hideaki Harada; Yasumasa Tada; Youichi Miyaoka; Hirofumi Fujishiro
Journal:  J Gastroenterol       Date:  2019-06-25       Impact factor: 7.527

2.  Circulating brain-derived neurotrophic factor, leptin, neuropeptide Y, and their clinical correlates in cystic fibrosis: a cross-sectional study.

Authors:  Jan K Nowak; Mariusz Szczepanik; Magdalena Trypuć; Andrzej Pogorzelski; Waldemar Bobkowski; Marcin Grytczuk; Alina Minarowska; Rafał Wójciak; Jaroslaw Walkowiak
Journal:  Arch Med Sci       Date:  2018-04-23       Impact factor: 3.318

3.  Leptin gene variants and colorectal cancer risk: Sex-specific associations.

Authors:  Kelsey A Chun; Jonathan M Kocarnik; Sheetal S Hardikar; Jamaica R Robinson; Sonja I Berndt; Andrew T Chan; Jane C Figueiredo; Noralane M Lindor; Mingyang Song; Robert E Schoen; Richard B Hayes; John D Potter; Rami Nassir; Stéphane Bézieau; Loic Le Marchand; Martha L Slattery; Emily White; Ulrike Peters; Polly A Newcomb
Journal:  PLoS One       Date:  2018-10-31       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.